2m 2m 2m 2m 2m 2m 2m
Abbott Laborator (ABT)
NYSE
$89.75+$1.92 (+2.19%)
Price as of Jun 23, 2026 5:39 PM EDT- $153.0BMarket Cap
- -32.74%1-Year Change
- Medical DevicesIndustry
Abbott Laborator (ABT)
$89.75+$1.92 (+2.19%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 44.3B +5.67% | 42.0B +4.59% | 40.1B -8.12% | 43.7B +1.34% | |
Cost of Revenue | 19.3B +3.28% | 18.7B +4.07% | 18.0B -6.10% | 19.1B +3.26% | |
Gross Profit | 25.0B +7.59% | 23.2B +5.01% | 22.1B -9.70% | 24.5B -0.11% | |
Sales and Marketing Expense | 12.3B +5.43% | 11.7B +6.83% | 10.9B -2.66% | 11.2B -0.67% | |
Research and Development Expense | -2.9B +3.45% | -2.8B +3.76% | -2.7B -5.09% | -2.9B +5.32% | |
Depreciation and Amortization Expense | 1.7B -10.44% | 1.9B -4.48% | 2.0B -2.33% | 2.0B -1.66% | |
Total Operating Expenses | 36.3B +3.27% | 35.1B +4.44% | 33.6B -4.70% | 35.3B +1.85% | |
Operating Profit | 8.1B +17.99% | 6.8B +5.36% | 6.5B -22.53% | 8.4B -0.75% | |
Interest Income | 308.0M -10.47% | 344.0M -10.65% | 385.0M +110.38% | 183.0M +325.58% | |
Interest Expense | -185.0M -13.95% | -215.0M -66.25% | -637.0M +14.16% | -558.0M +4.69% | |
Interest Income and Expense and Net | 123.0M -4.65% | 129.0M +151.19% | -252.0M -32.80% | -375.0M -23.47% | |
Total Nonoperating Income and Expense | 548.0M +45.74% | 376.0M -21.50% | 479.0M +49.22% | 321.0M +15.88% | |
Income before Taxes | 8.5B +20.72% | 7.0B +5.24% | 6.7B -19.77% | 8.3B +1.16% | |
Income Taxes | 1.9B +130.40% | -6.4B -778.96% | 941.0M -31.46% | 1.4B +20.44% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 6.5B -51.32% | 13.4B +134.18% | 5.7B -17.45% | 6.9B -1.95% | |
Net Income from Continuing Operations Applicable to Common | 8.5B +20.72% | 7.0B +5.24% | 6.7B -19.77% | 8.3B +1.16% | |
Basic EPS and Net Income | 3.73 -51.37% | 7.67 +133.84% | 3.28 -16.75% | 3.94 -0.76% | |
Diluted EPS and Net Income | 3.72 -51.31% | 7.64 +134.36% | 3.26 -16.62% | 3.91 -0.76% | |
Basic Weighted Average Shares | 1.7B +0.06% | 1.7B 0.00% | 1.7B -0.74% | 1.8B -1.24% | |
Diluted Weighted Average Shares | 1.7B 0.00% | 1.7B -0.06% | 1.7B -0.85% | 1.8B -1.40% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 8.5B +11.90% | 7.6B +10.44% | 6.9B -30.22% | 9.9B +0.85% | |
Short-Term Investments | 417.0M +18.80% | 351.0M -8.36% | 383.0M +32.99% | 288.0M -36.00% | |
Cash and Cash Equivalents and Short-Term Investments | 8.9B +12.20% | 8.0B +9.45% | 7.3B -28.43% | 10.2B -0.77% | |
Total Current Assets | 26.0B +9.89% | 23.7B +4.35% | 22.7B -10.13% | 25.2B +4.06% | |
Accumulated Depreciation | 13.4B +10.96% | 12.1B +2.57% | 11.8B +6.60% | 11.1B +6.20% | |
Property and Plant and Equipment and Net | 11.8B +10.87% | 10.7B +4.96% | 10.2B +10.83% | 9.2B +2.27% | |
Total Long-Term Assets | 11.8B +10.87% | 10.7B +4.96% | 10.2B +10.83% | 9.2B +2.27% | |
Total Assets | 86.7B +6.51% | 81.4B +11.20% | 73.2B -1.64% | 74.4B -1.01% | |
Income Taxes Payable | 569.0M -4.21% | 594.0M +20.73% | 492.0M +43.44% | 343.0M +12.09% | |
Total Short-Term Debt | 3.0B +102.20% | 1.5B +38.89% | 1.1B -52.02% | 2.3B +198.54% | |
Total Current Liabilities | 16.5B +16.52% | 14.2B +2.28% | 13.8B -10.64% | 15.5B +18.19% | |
Total Long-Term Debt | 9.9B -21.62% | 12.6B -7.16% | 13.6B -6.36% | 14.5B -16.04% | |
Total Long-Term Liabilities | 9.9B -21.62% | 12.6B -7.16% | 13.6B -6.36% | 14.5B -16.04% | |
Total Liabilities | 16.5B +16.52% | 14.2B +2.28% | 13.8B -10.64% | 15.5B +18.19% | |
Retained Earnings | -6.0B -24.10% | -7.9B +0.85% | -7.8B -2.63% | -8.1B -3.86% | |
Total Stockholders Equity | 52.1B +9.37% | 47.7B +23.47% | 38.6B +5.23% | 36.7B +2.47% | |
Total Shares Outstanding | 2.0B +0.27% | 2.0B +0.18% | 2.0B +0.07% | 2.0B +0.06% | |
Cash Flow | |||||
Cash from Operating Activities | 9.6B +11.78% | 8.6B +17.86% | 7.3B -24.21% | 9.6B -9.04% | |
Capital Expenditures | 2.2B -1.63% | 2.2B +0.23% | 2.2B +23.92% | 1.8B -5.73% | |
Cash from Investing Activities | -2.4B +3.59% | -2.3B -25.38% | -3.1B +80.06% | -1.7B -13.35% | |
Dividends Paid | 4.1B +7.30% | 3.8B +7.87% | 3.6B +7.46% | 3.3B +3.34% | |
Cash from Financing Activities | -6.3B +16.75% | -5.4B -23.79% | -7.1B -7.14% | -7.6B +38.99% | |
Financials Ratio | |||||
Gross Margin | 56.42% +1.82% | 55.41% +0.41% | 55.18% -1.72% | 56.15% -1.43% | |
Operating Margin | 18.17% +11.66% | 16.27% +0.73% | 16.15% -15.69% | 19.16% -2.06% | |
Return on Assets | 7.76% -55.23% | 17.33% +123.61% | 7.75% -16.34% | 9.27% -3.19% | |
Return on Equity | 13.07% -57.92% | 31.07% +104.38% | 15.20% -20.52% | 19.13% -7.23% | |
Revenue Growth | 5.67% +23.50% | 4.59% +156.54% | -8.12% -705.05% | 1.34% -94.52% | |
Current Ratio | 1.58 -5.69% | 1.67 +2.02% | 1.64 +0.58% | 1.63 -11.95% | |
Cash Ratio | 0.52 -3.98% | 0.54 +7.99% | 0.50 -21.91% | 0.64 -14.67% | |
Debt-to-Equity Ratio | 0.25 -16.30% | 0.30 -22.09% | 0.38 -16.82% | 0.46 -9.32% | |
Debt-to-Assets Ratio | 0.15 -14.06% | 0.17 -13.47% | 0.20 -11.01% | 0.23 -6.12% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow